These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1363 related articles for article (PubMed ID: 33851953)

  • 1. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
    Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
    Mosenzon O; Wiviott SD; Heerspink HJL; Dwyer JP; Cahn A; Goodrich EL; Rozenberg A; Schechter M; Yanuv I; Murphy SA; Zelniker TA; Gause-Nilsson IAM; Langkilde AM; Fredriksson M; Johansson PA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS; Raz I
    Diabetes Care; 2021 Aug; 44(8):1805-1815. PubMed ID: 34233928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
    N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
    N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Oyama K; Raz I; Cahn A; Goodrich EL; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Mosenzon O; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2022 Sep; 7(9):914-923. PubMed ID: 35857296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
    Yu MK; Vart P; Jongs N; Correa-Rotter R; Rossing P; McMurray JJV; Hou FF; Douthat W; Khullar D; Langkilde AM; Wheeler DC; Heerspink HJL; Chertow GM
    J Gen Intern Med; 2024 May; 39(6):921-930. PubMed ID: 38097862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.